Log In
Print
BCIQ
Print
Print this Print this
 

MGCD265

  Manage Alerts
Collapse Summary General Information
Company Mirati Therapeutics Inc.
DescriptionOral small molecule, multitargeted kinase inhibitor that targets the c-MET, VEGF receptors 1, 2, 3, Tie-2 and RON receptor tyrosine kinases
Molecular Target c-Met receptor tyrosine kinase (c-MET) (MET) (HGFR) (c-Met proto-oncogene) ; Vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-2) (KDR/Flk-1)
Mechanism of ActionVascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) kinase inhibitor; Vascular endothelial growth factor (VEGF) receptor 1 (Flt-1) kinase inhibitor; c-Met receptor tyrosine kinase inhibitor; AXL receptor tyrosine kinase (AXL) inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today